SOS1 inhibitor combinations overcome KRAS inhibitor resistance

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-08-12 DOI:10.1038/s43018-024-00801-5

引用次数: 0

Abstract

Combining SOS1 inhibitors with KRAS inhibitors improved the depth and durability of response in lung and colorectal cancer models. Restoration of response was observed in preclinical models rendered resistant to KRAS inhibitors. These results highlight the potential of SOS1 inhibitors to broaden the response to KRAS inhibitors in the clinic.

Abstract Image

查看原文本刊更多论文

SOS1 抑制剂组合克服了 KRAS 抑制剂的耐药性

在肺癌和结直肠癌模型中，将 SOS1 抑制剂与 KRAS 抑制剂结合使用可提高反应的深度和持久性。在对 KRAS 抑制剂耐药的临床前模型中也观察到了反应的恢复。这些结果凸显了 SOS1 抑制剂在临床上扩大对 KRAS 抑制剂反应的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.